Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial
Pietro Invernizzi, Marco Carbone, David Jones, et al.
Liver International (2023) Vol. 43, Iss. 7, pp. 1507-1522
Open Access | Times Cited: 23

Showing 23 citing articles:

Primary biliary cholangitis
Atsushi Tanaka, Xiong Ma, Atsushi Takahashi, et al.
The Lancet (2024) Vol. 404, Iss. 10457, pp. 1053-1066
Open Access | Times Cited: 20
ROS/RNS as molecular signatures of chronic liver diseases
Zhaodi Che, Ziyuan Zhou, Siqi Li, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 11, pp. 951-967
Closed Access | Times Cited: 37
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, et al.
Cells (2024) Vol. 13, Iss. 18, pp. 1580-1580
Open Access | Times Cited: 6
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, et al.
Journal of Pharmacy & Pharmaceutical Sciences (2023) Vol. 26
Open Access | Times Cited: 14
Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?
Xin Luo, Lungen Lu
Journal of Clinical and Translational Hepatology (2024) Vol. 12, Iss. 6, pp. 581-588
Open Access | Times Cited: 5
Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice
Elena Góméz, J.L. Montero, Ezequiel Molina, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 12, pp. 1604-1615
Open Access | Times Cited: 4
Primary Biliary Cholangitis: Personalizing Second-Line Therapies-R1
Cynthia Levy, Christopher L. Bowlus
Hepatology (2024)
Closed Access | Times Cited: 4
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Marilena Durazzo, Arianna Ferro, Víctor Navarro-Tableros, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 121-121
Open Access
Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor
Beatrice Noce, Sara Marchese, Marta Massari, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Evaluation of the Inhibitory Potential of Apigenin and Related Flavonoids on Various Proteins Associated with Human Diseases Using AutoDock
Tanat Peanlikhit, Uma K. Aryal, James S. Welsh, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2548-2548
Open Access
New Therapies on the Horizon for Primary Biliary Cholangitis
Atsushi Tanaka
Drugs (2023) Vol. 84, Iss. 1, pp. 1-15
Closed Access | Times Cited: 10
Molecular Pathways Governing the Termination of Liver Regeneration
Lianne R. de Haan, Rowan F. van Golen, Michal Heger
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 500-558
Closed Access | Times Cited: 3
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Laurent Lam, Pierre‐Antoine Soret, Sara Lemoinne, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 12, pp. 2432-2441.e2
Open Access | Times Cited: 2
Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Jing Liao, Zhaoguang Lai, Guangyi Huang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 116042-116042
Open Access | Times Cited: 6
NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation
Eun Bee Oh, Hye Ji Shin, Hyunseong Yu, et al.
Life Sciences (2024), pp. 123061-123061
Closed Access | Times Cited: 2
Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Nicholas Cumpian, Gina Choi, Sammy Saab
Digestive Diseases and Sciences (2024)
Closed Access | Times Cited: 2
Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis
Marco Carbone, Alessio Gerussi, Vincenzo Cardinale, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 9, pp. 1461-1474
Closed Access | Times Cited: 1
Primary Biliary Cholangitis: Updates in Management and Goals of Treatment
Kaitlyn Carlson, Madeleine Hines Salge, George Cholankeril
Current Hepatology Reports (2024) Vol. 23, Iss. 3, pp. 349-354
Closed Access
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
Conrado Fernández-Rodrı́guez, María Luisa Gutiérrez García, Antonio Olveira
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 91-92
Closed Access
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Teng Moua, Misbah Baqir, Jay H. Ryu
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6304-6304
Open Access
Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis
Zakary Warsop, Nikhil Anand, Husam Al Maliki, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 12, pp. 1133-1133
Open Access
New therapies for primary biliary cholangitis usher in a personalised approach to treatment
Nicole L. France
Drugs & Therapy Perspectives (2024)
Closed Access
Current and future opportunities for the management of primary biliary cholangitis
Sandra Naffouj, Jennifer Wang
Frontiers in Gastroenterology (2023) Vol. 2
Open Access | Times Cited: 1
Page 1

Scroll to top